[96a5a0]: / output / allTrials / identified / NCT03339882_identified.json

Download this file

448 lines (448 with data), 18.7 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
{
"info": {
"nct_id": "NCT03339882",
"official_title": "The Effect of Remifemin in Preventing the Climacteric Symptoms Caused by LHRH-a Treatment in Breast Cancer: a Randomized II-stage Clinic Research",
"inclusion_criteria": "1. provision of informed consent\n2. clinical stage I~IIIC\n3. histologically proven invasive breast cancer\n4. women defined as premenopausal according to NCCN guideline\n5. plan to accept the LHRH-a as endocrine treatment or ovarian function protection\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 55 Years",
"exclusion_criteria": "1. clinical evidence of metastatic disease\n2. bilateral oophorectomy\n3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements\n4. patients who accepted anti-cancer treatment before\n5. previous hormonal therapy as adjuvant treatment for non-cancer disease\n6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied\n7. treatment with a non-approved or experimental drug during 1 month before entry into the study\n8. history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)\n9. leukopenia and/or thrombocytopenia\n10. history of ocular fundus diseases\n11. history of thromboembolic diseases\n12. history of osteoporotic fractures",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "1. provision of informed consent",
"criterions": [
{
"exact_snippets": "provision of informed consent",
"criterion": "informed consent",
"requirements": [
{
"requirement_type": "provision",
"expected_value": true
}
]
}
]
},
{
"line": "2. clinical stage I~IIIC",
"criterions": [
{
"exact_snippets": "clinical stage I~IIIC",
"criterion": "clinical stage",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 1,
"unit": "N/A"
},
{
"operator": "<=",
"value": 3,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "3. histologically proven invasive breast cancer",
"criterions": [
{
"exact_snippets": "histologically proven invasive breast cancer",
"criterion": "invasive breast cancer",
"requirements": [
{
"requirement_type": "diagnosis method",
"expected_value": "histologically proven"
}
]
}
]
},
{
"line": "4. women defined as premenopausal according to NCCN guideline",
"criterions": [
{
"exact_snippets": "women defined as premenopausal according to NCCN guideline",
"criterion": "premenopausal status",
"requirements": [
{
"requirement_type": "definition",
"expected_value": "NCCN guideline"
}
]
}
]
},
{
"line": "5. plan to accept the LHRH-a as endocrine treatment or ovarian function protection",
"criterions": [
{
"exact_snippets": "accept the LHRH-a as endocrine treatment",
"criterion": "LHRH-a acceptance",
"requirements": [
{
"requirement_type": "intention",
"expected_value": "endocrine treatment"
}
]
},
{
"exact_snippets": "accept the LHRH-a as ... ovarian function protection",
"criterion": "LHRH-a acceptance",
"requirements": [
{
"requirement_type": "intention",
"expected_value": "ovarian function protection"
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
},
{
"line": "Must have maximum age of 55 Years",
"criterions": [
{
"exact_snippets": "maximum age of 55 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 55,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "1. clinical evidence of metastatic disease",
"criterions": [
{
"exact_snippets": "clinical evidence of metastatic disease",
"criterion": "metastatic disease",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "2. bilateral oophorectomy",
"criterions": [
{
"exact_snippets": "bilateral oophorectomy",
"criterion": "bilateral oophorectomy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "3. patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements",
"criterions": [
{
"exact_snippets": "patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements",
"criterion": "compliance with trial requirements",
"requirements": [
{
"requirement_type": "likelihood",
"expected_value": true
}
]
}
]
},
{
"line": "4. patients who accepted anti-cancer treatment before",
"criterions": [
{
"exact_snippets": "patients who accepted anti-cancer treatment before",
"criterion": "anti-cancer treatment",
"requirements": [
{
"requirement_type": "acceptance",
"expected_value": true
},
{
"requirement_type": "timing",
"expected_value": "before"
}
]
}
]
},
{
"line": "5. previous hormonal therapy as adjuvant treatment for non-cancer disease",
"criterions": [
{
"exact_snippets": "previous hormonal therapy",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "previous treatment",
"expected_value": true
}
]
},
{
"exact_snippets": "adjuvant treatment",
"criterion": "adjuvant treatment",
"requirements": [
{
"requirement_type": "treatment type",
"expected_value": true
}
]
},
{
"exact_snippets": "non-cancer disease",
"criterion": "non-cancer disease",
"requirements": [
{
"requirement_type": "disease type",
"expected_value": "non-cancer"
}
]
}
]
},
{
"line": "6. patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied",
"criterions": [
{
"exact_snippets": "patients unwilling to stop taking any drug known to affect sex hormonal status",
"criterion": "willingness to stop taking drugs affecting sex hormonal status",
"requirements": [
{
"requirement_type": "willingness",
"expected_value": true
}
]
},
{
"exact_snippets": "previous history of invasive malignancy within the last 5 years",
"criterion": "history of invasive malignancy",
"requirements": [
{
"requirement_type": "time since last occurrence",
"expected_value": {
"operator": "<=",
"value": 5,
"unit": "years"
}
}
]
},
{
"exact_snippets": "squamous or basal cell carcinoma of the skin",
"criterion": "squamous or basal cell carcinoma of the skin",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "carcinoma in situ of the cervix, adequately cone biopsied",
"criterion": "carcinoma in situ of the cervix",
"requirements": [
{
"requirement_type": "treatment",
"expected_value": "adequately cone biopsied"
}
]
}
]
},
{
"line": "7. treatment with a non-approved or experimental drug during 1 month before entry into the study",
"criterions": [
{
"exact_snippets": "treatment with a non-approved or experimental drug during 1 month before entry into the study",
"criterion": "treatment with a non-approved or experimental drug",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": "1 month before entry into the study"
}
]
}
]
},
{
"line": "8. history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)",
"criterions": [
{
"exact_snippets": "history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency)",
"criterion": "bleeding diathesis",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
},
{
"exact_snippets": "long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)",
"criterion": "anticoagulant therapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": "long term"
},
{
"requirement_type": "exclusion",
"expected_value": [
"antiplatelet therapy",
"low dose warfarin"
]
}
]
}
]
},
{
"line": "9. leukopenia and/or thrombocytopenia",
"criterions": [
{
"exact_snippets": "leukopenia",
"criterion": "leukopenia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "thrombocytopenia",
"criterion": "thrombocytopenia",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "10. history of ocular fundus diseases",
"criterions": [
{
"exact_snippets": "history of ocular fundus diseases",
"criterion": "ocular fundus diseases",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "11. history of thromboembolic diseases",
"criterions": [
{
"exact_snippets": "history of thromboembolic diseases",
"criterion": "thromboembolic diseases",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "12. history of osteoporotic fractures",
"criterions": [
{
"exact_snippets": "history of osteoporotic fractures",
"criterion": "osteoporotic fractures",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}